OVERVIEW
Entero Therapeutics’ product portfolio is built around its three proprietary technologies – latiglutenase, a potentially first-in-class oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of celiac disease, capeserod, a selective 5-HT4 receptor partial agonist being developed for multiple gastrointestinal indications, and adrulipase, a recombinant lipase designed to enable the digestion of fats and other nutrients in patients with exocrine pancreatic insufficiency.
